UCHL1 and neoplasm: Within the group of patients with locoregional recurrence (n = 38), we observed not only a significant delay in tumor relapse for UCHL1-related HNSC (Figure 4D), but also a shift from UCHL1-related to others phenotype in 66% of cases (Figure 4E).